Close

Glenmark announces the Discovery of a novel chemical entity ‘GRC 17536’, a potential first-in-class molecule globally

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Glenmark Pharmaceuticals announced the discovery of a Novel Chemical Entity(NCE) ‘GRC 17536’. The new NCE program is targeting TRPA1 recept or antagonists for pain and respiratory disorders. TRPA1 belongs to Transient Receptor Potential
(TRP) family of ion channels, which have generated a lot of interest as pain targets due to their
distinguishing role in peripheral and/or central pain signal transmission.

Glenmark has selected a lead molecule named GRC 17536 which is currently finishing up Phase 1
enabling GLP studies. Preclinical studies have been completed and Glenmark plans to file the
Phase 1 application in January 2011. This is another potential first-in-class molecule globally for
Glenmark

Commenting on this discovery, Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals ltd
mentioned “We are glad to announce our third novel molecule discovery in the TRP space. Both
our earlier TRP molecules i.e. TRPV1 and TRPV3 resulted in outlicensing deals for the company.
GRC 17536 which is a TRPA1 receptor antagonist is another potential first-in-class globally and
we are encouraged by the results shown by the molecule in animal studies. GRC 17536 is highly
selective even when compared with other TRPs and can be administered orally”

 

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back